Eterna Therapeutics
Yahoo Finance • 2 months ago
Ernexa Therapeutics to Participate in Virtual Investor Closing Bell Series
Live video webcast with Sanjeev Luther, President and Chief Executive Officer of Ernexa Therapeutics, on Wednesday, February 25th at 4:00 PM ET Register here CAMBRIDGE, Mass., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasd... Full story
Yahoo Finance • 2 months ago
Ernexa Therapeutics Announces Pricing of $10.5 Million Public Offering
CAMBRIDGE, Mass., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics Inc. (Nasdaq: ERNA) (“Ernexa” or the “Company”), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, t... Full story
Yahoo Finance • 2 months ago
Ernexa Therapeutics Participates in Virtual Investor “What This Means” Segment Highlighting Recent Successful Pre-IND Meeting with U.S. FDA
Access the “What This Means” segment here CAMBRIDGE, Mass., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune... Full story
Yahoo Finance • 4 months ago
Ernexa Therapeutics Presents New Preclinical Data at American Society of Hematology (ASH) Annual Meeting on Lead Cell Therapy Candidate for Treatment of Ovarian Cancer
CAMBRIDGE, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced the presentation o... Full story
Yahoo Finance • 4 months ago
Ernexa Therapeutics Strengthens Scientific and Medical Advisory Board with Appointment of Leading Oncologist Dr. Ira S. Winer, M.D., Ph.D., FACOG
CAMBRIDGE, Mass., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced the appointment of... Full story
Yahoo Finance • 5 months ago
Ernexa Therapeutics Reports Strong Quarterly Performance, Highlighting Operational Execution and Progress Toward First-in-Human Cell Therapy Trials
The Company’s operating loss declined by 44% year-over-year, reflecting its continued laser focus on relentless execution and progress in operational excellence Continued progress with lead program, ERNA-101, toward first-in-human Phase 1... Full story
Yahoo Finance • 5 months ago
Ernexa Therapeutics Showcases Strategic Partnership with Cellipont Bioservices to Advance Toward First-in-Human Trials on Virtual Investor “What This Means” Platform
Access the “What This Means” segment here CAMBRIDGE, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune... Full story
Yahoo Finance • 6 months ago
BC-Most Active Stocks
NEW YORK (AP) — prices for the Nasdaq composite, NYSE and NYSE American listed most active stocks. Nasdaq most active stocks: Stock Name Volume High Low Last Change Cambium Networks Corp. 245,205,302 2.45 1.68 1.715 +1.097 Founder Group... Full story
Yahoo Finance • 6 months ago
Ernexa Therapeutics to Deliver Company Presentation at the Annual Cell & Gene Meeting on the Mesa
CAMBRIDGE, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced its upcoming company presentation a... Full story
Yahoo Finance • 7 months ago
Ernexa Therapeutics President & CEO Sanjeev Luther to Present on Expert Panel at 5th Annual iPSC Drug Development Summit
CAMBRIDGE, Mass., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced that its President and CEO, Sanjee... Full story
Yahoo Finance • 7 months ago
Ernexa Therapeutics to Present New Data in Oral Presentation at AACR Special Conference in Cancer Research
CAMBRIDGE, Mass., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced preclinical data will be presented... Full story
Yahoo Finance • 7 months ago
Ernexa Therapeutics Announces Presentation At The H.C. Wainwright 27th Annual Global Investment Conference
CAMBRIDGE, Mass., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced it will be featur... Full story
Yahoo Finance • 9 months ago
Ernexa regains Nasdaq compliance, continues trading on exchange
CAMBRIDGE, Mass. - Ernexa Therapeutics (NASDAQ:ERNA) has regained compliance with Nasdaq’s minimum bid price requirement for continued listing, the company announced Wednesday. The biotech firm, currently valued at $14.1 million, has seen... Full story
Yahoo Finance • 9 months ago
Ernexa Therapeutics changes independent auditor to Haskell & White
Ernexa Therapeutics Inc. (NASDAQ:ERNA), a small-cap biotech company currently valued at $13.54 million and showing signs of financial strain according to InvestingPro data, announced a change in its independent registered public accounting... Full story
Yahoo Finance • 10 months ago
Ernexa Therapeutics Expands Advisory Board to Form Integrated Scientific and Medical Advisory Board as it Prepares for Clinical Development
CAMBRIDGE, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced the expansion of its Scientific Adv... Full story
Yahoo Finance • 10 months ago
Ernexa Therapeutics registers 57M shares for resale
* Ernexa Therapeutics (NASDAQ:ERNA [https://seekingalpha.com/symbol/ERNA]) is registering 57.05M shares of common stock for resale by selling stockholders. * Includes 47.7M outstanding shares and 9.3M shares issuable upon exercise of p... Full story
Yahoo Finance • 10 months ago
Ernexa Therapeutics announces 1-for-15 reverse stock split
Ernexa Therapeutics (ERNA) announced a reverse stock split of its issued and outstanding shares of common stock, par value $0.005 per share at a ratio of 1-for-15, effective June 12, 2025 at 12:01 a.m. Eastern Time. The Company’s Common St... Full story
Yahoo Finance • 10 months ago
Ernexa Therapeutics stock plummets on announcing 1-for-15 reverse stock split
* Ernexa Therapeutics (NASDAQ:ERNA [https://seekingalpha.com/symbol/ERNA]) trades -19% as the Co. announced a reverse stock split of its issued and outstanding shares of common stock, par value $0.005 per share, at a ratio of 1-for-15 [h... Full story
Yahoo Finance • 10 months ago
Ernexa Therapeutics Announces 1-for-15 Reverse Stock Split
CAMBRIDGE, Mass., June 10, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced a reverse stock split of its issued... Full story
Yahoo Finance • 11 months ago
Ernexa Therapeutics Announces New Data to be Presented at ASCO Annual Meeting 2025
CAMBRIDGE, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced that new data will be presented at t... Full story
